ALT-B4

About Alteogen

Alteogen's mission is to develop innovative biobetter and biosimilar pharmaceuticals through its proprietary technology platforms. The company achieved a watershed financial performance in 2025, with consolidated revenue of KRW 2.159 trillion (approx. $1.6B USD) and net profit of KRW 1.443 trillion, driven by its platform-centric business model of licensing and profit-sharing. Its strategy focuses on expanding its technology moat through R&D and securing global partnerships to commercialize its pipeline, while transitioning to a mature, shareholder-returning entity.

Therapeutic Areas